美国艾滋病研究发展态势分析
|
摘要
目的分析2013—2017年美国在艾滋病研究领域的资金投入、科研产出、重点研发机构和主要研究领域,为我国传染病重大专项的管理和布局提供参考。方法以艾滋病病毒(HIV)艾滋病(ADIS)为主题,通过Web of Science、INNOGRAPHY、Cortellis、Clinical trails、NIH RePORTER几个权威数据库获得数据,并运用VOSviwer软件对研究主题进行可视化分析。结果 2013—2017年,美国政府在艾滋病领域的研究资助超过60亿美元,美国国立卫生研究院和美国艾滋病研究基金会每年的资助基金均呈逐年增长趋势。美国研究论文发文量占全球总量的38.12%,高被引论文发文量居全球首位,被引频次进入全球1%、10%和热点论文的论文数量分别占总发文量的2.22%、15.36%和0.05%,论文被引的平均百分位为45.81%,专利申请和授权量居全球首位,牵头研发的药物数量全球占比58.57%,已获批上市药物全球占比21/39,牵头开展的临床试验数量全球占比36.92%。结论美国在艾滋病研究领域的资助力度正在不断加强,国家科研机构、大学和生物医药公司在基础研究领域和应用领域都具有较强的研究实力。
Objective To analyze the capital input, research output, key R&D institutions and major research fields of the United States in AIDS research during 2013-2017, so as to provide reference for the management of major infectious diseases programs in China. Methods Based on the theme of HIV/AIDS, data were obtained from several authoritative databases including Web of Science, INNOGRAPHY, Cortellis, Clinical Trails, and NIH RePORTER, and the results were visualized by VOSviewer software. Results During 2013-2017, the USA government funded more than $6 billion in the field of AIDS research and the annual grants of NIH and the American foundation for AIDS research continued to increase year by year. The proportion of published research papers in USA accounted for 38.12% of the global total, and the number of published papers with high citation rate ranked the first in the world. The papers with citation frequency ranking 1%, 10% and hot papers of the world accounted for 2.22%, 15.36% and 0.05% respectively, and the average proportion of papers cited was 45.81%. The number of patent applications and authorizations ranked the first in the world. The proportion of R&D drugs led by USA was 58.57%. The proportion of the approved drugs was 53.8% and the proportion of clinical trials accounted for 36.92% of the world. Conclusion The funding for HIV/AIDS research in USA is increasing. The national research institutions, universities and biopharmaceutical companies are strong in both AIDS basic research and application fields.
Objective To analyze the capital input, research output, key R&D institutions and major research fields of the United States in AIDS research during 2013-2017, so as to provide reference for the management of major infectious diseases programs in China. Methods Based on the theme of HIV/AIDS, data were obtained from several authoritative databases including Web of Science, INNOGRAPHY, Cortellis, Clinical Trails, and NIH RePORTER, and the results were visualized by VOSviewer software. Results During 2013-2017, the USA government funded more than $6 billion in the field of AIDS research and the annual grants of NIH and the American foundation for AIDS research continued to increase year by year. The proportion of published research papers in USA accounted for 38.12% of the global total, and the number of published papers with high citation rate ranked the first in the world. The papers with citation frequency ranking 1%, 10% and hot papers of the world accounted for 2.22%, 15.36% and 0.05% respectively, and the average proportion of papers cited was 45.81%. The number of patent applications and authorizations ranked the first in the world. The proportion of R&D drugs led by USA was 58.57%. The proportion of the approved drugs was 53.8% and the proportion of clinical trials accounted for 36.92% of the world. Conclusion The funding for HIV/AIDS research in USA is increasing. The national research institutions, universities and biopharmaceutical companies are strong in both AIDS basic research and application fields.
引文
[1] 国家卫生和计划生育委员会.中国卫生和计划生育统计年鉴[M].北京:中国协和医科大学出版社,2008-2017.
[2] 人民网-人民日报.习近平就做好艾滋病防治工作作出重要指示[EB/OL](2013-12-01)[2019-1-15].http://cpc.people.com.cn/n/2013/1201/c64094-23706413.html.
[3] 韩孟杰.贯彻落实防治艾滋病“十三五”行动计划将艾滋病持续控制在低流行水平[J].中国艾滋病性病,2018,24(1):2-4.
[4] 张宏梁,肖宏.国际重要艾滋病研究基金发展态势的信息研究[J].中国科学基金,2007,21(4):218-222.
[5] amfAR.amfAR Awards $1.4 Million in New Grants for HIV Cure Research[EB/OL].(2013-02-14)[2019-02-18].https://www.amfar.org/amfAR-Awards-New-Grants-for-HIV-Cure-Research/.
[6] amfAR.HIV Cure Research Gains Momentum from New amfAR Funding[EB/OL].(2014-07-09)[2019-02-18].https://www.amfar.org/Articles/In-The-Lab/2014/HIV-Cure--Research-Gains-Momentum-from-New-amfAR-Funding/.
[7] amfAR.amfAR Announces $100 Million Investment Strategy Aimed at Curing HIV[EB/OL].(2015-02-19)[2019-02-18].https://www.amfar.org/amfAR-Announces-100-Million-Investment-Strategy-Aimed-at-Curing-HIV/.
[8] amfAR Research Funding Targets Biggest Roadblocks to HIV Cure[EB/OL].(2016-06-01)[2019-02-18].https://www.amfar.org/pr-roadblocks/.
[9] amfAR New amfAR Grants Enlist Help of Bioengineers to Overcome Obstacles to Curing HIV[EB/OL].(2017-02-28)[2019-02-18].https://www.amfar.org/bioengineers-grants/.
[10] amfAR amfAR Renews Investment in Bioengineering Approaches to Curing HIV[EB/OL].(2018-02-15)[2019-02-18].https://www.amfar.org/Bioengineering-curing-HIV/.
[11] 吴尊友.艾滋病预防技术进展与防治策略[J].中华预防医学杂志,2018,52(12):1204-2019.
[12] 胡欣悦,汤勇力,王国庆,等.研发国际化、跨国知识网络与研发单元创新绩效--基于华为PCT专利(2002—2013年)的面板数据分析[J].系统工程理论与实践,2018,38(12):3124-3139.
[13] 郝聪颖,于琦,白碧玉,等.全球艾滋病领域研究论文合作分析[J].中国药物与临床,2019,19(2):193-197.
[14] 童嗣超,杨立英.艾滋病研究领域国际合作成果的文献计量分析[J].科学观察,2017,12(2):22-30.
[15] 杜建,唐小利.美国国立卫生研究院与中国国家自然科学基金资助艾滋病细分领域分析[J].中国预防医学杂志,2012,13(9):718-722.
[16] 吴尊友.艾滋病预防技术进展与防治策略[J].中华预防医学杂志,2018,52(12):1204-2019.
[2] 人民网-人民日报.习近平就做好艾滋病防治工作作出重要指示[EB/OL](2013-12-01)[2019-1-15].http://cpc.people.com.cn/n/2013/1201/c64094-23706413.html.
[3] 韩孟杰.贯彻落实防治艾滋病“十三五”行动计划将艾滋病持续控制在低流行水平[J].中国艾滋病性病,2018,24(1):2-4.
[4] 张宏梁,肖宏.国际重要艾滋病研究基金发展态势的信息研究[J].中国科学基金,2007,21(4):218-222.
[5] amfAR.amfAR Awards $1.4 Million in New Grants for HIV Cure Research[EB/OL].(2013-02-14)[2019-02-18].https://www.amfar.org/amfAR-Awards-New-Grants-for-HIV-Cure-Research/.
[6] amfAR.HIV Cure Research Gains Momentum from New amfAR Funding[EB/OL].(2014-07-09)[2019-02-18].https://www.amfar.org/Articles/In-The-Lab/2014/HIV-Cure--Research-Gains-Momentum-from-New-amfAR-Funding/.
[7] amfAR.amfAR Announces $100 Million Investment Strategy Aimed at Curing HIV[EB/OL].(2015-02-19)[2019-02-18].https://www.amfar.org/amfAR-Announces-100-Million-Investment-Strategy-Aimed-at-Curing-HIV/.
[8] amfAR Research Funding Targets Biggest Roadblocks to HIV Cure[EB/OL].(2016-06-01)[2019-02-18].https://www.amfar.org/pr-roadblocks/.
[9] amfAR New amfAR Grants Enlist Help of Bioengineers to Overcome Obstacles to Curing HIV[EB/OL].(2017-02-28)[2019-02-18].https://www.amfar.org/bioengineers-grants/.
[10] amfAR amfAR Renews Investment in Bioengineering Approaches to Curing HIV[EB/OL].(2018-02-15)[2019-02-18].https://www.amfar.org/Bioengineering-curing-HIV/.
[11] 吴尊友.艾滋病预防技术进展与防治策略[J].中华预防医学杂志,2018,52(12):1204-2019.
[12] 胡欣悦,汤勇力,王国庆,等.研发国际化、跨国知识网络与研发单元创新绩效--基于华为PCT专利(2002—2013年)的面板数据分析[J].系统工程理论与实践,2018,38(12):3124-3139.
[13] 郝聪颖,于琦,白碧玉,等.全球艾滋病领域研究论文合作分析[J].中国药物与临床,2019,19(2):193-197.
[14] 童嗣超,杨立英.艾滋病研究领域国际合作成果的文献计量分析[J].科学观察,2017,12(2):22-30.
[15] 杜建,唐小利.美国国立卫生研究院与中国国家自然科学基金资助艾滋病细分领域分析[J].中国预防医学杂志,2012,13(9):718-722.
[16] 吴尊友.艾滋病预防技术进展与防治策略[J].中华预防医学杂志,2018,52(12):1204-2019.